Tiny study tests Tumor-Injected drug plus immunotherapy for tough cancers
NCT ID NCT05383170
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new drug called CyPep-1, injected directly into tumors, combined with the immunotherapy pembrolizumab (Keytruda) in 6 people with advanced head and neck cancer, melanoma, or triple-negative breast cancer. The main goal was to check safety and side effects, not to cure the disease. Because it was very small and early, we cannot draw strong conclusions about how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CyPep-1 (a drug injected into tumors) and pembrolizumab (an immunotherapy drug, also known as Keytruda)
- What this could lead to
- If it works, this combination could shrink tumors and help control advanced cancers that are hard to treat.
- What could go wrong
- This is a very early, tiny study (only 6 people) focused on safety, not effectiveness. The results may not apply to larger groups, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AP-HM - Hôpital de la Timone
Marseille, France
-
Azienda Ospedaliero Universitaria Senese
Siena, Italy
-
CHRU de Besançon
Besançon, France
-
CHU Lille
Lille, France
-
Centre Leon Berard
Lyon, France
-
City Of Hope
Duarte, California, 91010, United States
-
Clinica Universidad de Navarra Madrid
Madrid, Spain
-
Clinica Universidad de Navarra Pamplona
Pamplona, Spain
-
EMC
Rotterdam, Netherlands
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Hospital Universitario 12 de Octubre
Madrid, Spain
-
Hospital Universitario HM Sanchinarro
Madrid, Spain
-
Hospital Universitario Virgen Macarena
Seville, Spain
-
Houston Methodist
Houston, Texas, 77030, United States
-
Hôpital Saint Louis - AP-HP
Paris, France
-
Institut Bergonie
Bordeaux, France
-
Institut Paoli Calmettes
Marseille, France
-
Institute Gustave Roussy
Villejuif, France
-
Istituto Europeo di Oncologia
Milan, Italy
-
Maastricht UMC
Maastricht, Netherlands
-
NKI/AvL
Amsterdam, Netherlands
-
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, 75246, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213-2582, United States
-
Vall d'Hebron (VHIO)
Barcelona, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
- Can a pill combo outpace chemotherapy for aggressive breast cancer?
- Can a new biologic drug shrink advanced melanoma tumors?
- Blood tests could reveal hidden resistance in breast cancer
- Triple threat: three new targeted drugs join forces with immunotherapy to attack Hard-to-Treat breast cancer
- Engineered immune cells take aim at Hard-to-Treat cancers